2025 was a strong year for drugs approved by the agency with record-high outsourcing penetration. Lonza, Thermo Fisher, and Catalent remain the leaders.
Investments in its network include the company’s CDMO business in the Toronto area, where it is building a new GMP biologics facility slated for completion in 2026.
The agency will select new pharma manufacturing facilities for the pilot aimed at reducing inspection-related delays and creating a more predictable regulatory pathway.
It is the largest increase of the four major industries tracked by commercial real estate firm Newmark, which analysts contend is the start of a super-cycle for the sector.
In addition to new sites, which will be announced later, the company will expand its existing manufacturing facilities in Beijing, Qingdao, Taizhou, and Wuxi.
It will take the company years to recoup its investment in the large-scale mammalian drug substance facility, acquired in 2024 from Roche for $1.2 billion.
While recent setbacks have hit its cell and gene therapy business, the contract development and manufacturing organization says fundamentals are strong.
The Swiss-headquartered CDMO is acquiring a commercial-scale site in Wilmington, Delaware and a clinical active pharmaceutical ingredient facility in Athens, Georgia.
Atradius and GlobalData see Britain as having a competitive advantage in attracting pharmaceutical production, thanks to tariff exemptions for drug exports to U.S.
The CDMO’s Plants 1 through 4 remained stable while providing a “solid” operational base last year, the company said, with Plant 5 to begin contributing to revenue in 2026.
The building of global facilities, forging of partnerships, and FDA validation have positioned the company to support commercial-scale cell therapy production.
The expansion of the facility in Holly Springs, North Carolina will boost production volume and scale capacity while significantly increasing output, the company said.
The CDMO is looking to mitigate supply chain risks by integrating modularization and standardization into its network, offering customers flexibility and scalability.
Tim Hunt, CEO of the Alliance for Regenerative Medicine, contends that CGT companies are emerging stronger in 2026 from “hard lessons” learned after years of volatility.
As part of a previous pledge to invest $55 billion in the U.S., the drugmaker announced it will build two new manufacturing facilities in North Carolina and Pennsylvania.
The Japanese drugmaker is doubling down on its manufacturing investment in the antibody-drug conjugate market, where it remains the dominant global player.
Manufacturers face growing pressure to align drug design, production strategy, logistics, and workforce planning to ensure reliable, at-scale delivery.
Biomanufacturing scaling and supply chain resilience are top priorities for biopharma companies as they look to mitigate risks and capitalize on growth opportunities.
Revenues for publicly traded contract manufacturers will have doubled in five years when their fourth-quarter 2025 results are released, predicts new report from JLL.
In exchange for discounts to list prices on select medicines, the companies will receive relief from potential pharmaceutical tariffs over a three-year period.
Large pharmaceutical companies have promised to invest more than $370 billion over the next five years in the U.S., driven by Trump’s threat of pharma-specific tariffs.
The agency cited “significant violations” of current Good Manufacturing Practice regulations for finished pharmaceuticals at Novo Nordisk’s Bloomington facility.